InvestorsHub Logo
Replies to #707 on SPYR Inc (SPYR)

Nightridertwou

08/01/17 2:53 PM

#708 RE: bonehead41 #707

As a matter of fact, just this morning the company re-iterated its commitment to its growth in the eSports space, announcing it will be attending the Star TrekTM Convention in Las Vegas, which runs from August 2-6.
In anticipation of the release of Pocket Starships: STAR TREK Borg Invasion, SPYR will be participating in the following three separate panels at this year's convention:
Thursday, August 3 @ 4:30pm in the DeForest Kelley Theatre
Two Universes Collide Panel
Friday, August 4 @ 11:45am in the DeForest Kelley Theatre
Inside Trek: Star Trek Gamers & Their Games
Friday, August 4 @ 3:30pm on the CBS All Access Stage
Inside Trek: Ralf Adam, SPYR GAMES
"Our participation in the Star Trek Convention will allow us to get the word out to Star Trek fans about the soon to be released Pocket Starships: STAR TREK Borg Invasion," said SPYR CEO & President, James R. Thompson. "We hope that they become as excited about the game as we are!"
Although the news is nothing earth shattering, if the company's soon to be released game, Pocket Starships: STAR TREK Borg Invasion, is extremely well received in the gaming world, we could be on the verge of a whole new ballgame for SPYR.

Going Coastal

08/02/17 3:56 PM

#709 RE: bonehead41 #707

You do realize this is all temporary don't you? The Caveat Emptor and Pink designation by the OTC (to help out whiny shorts) is only a temporary designation and will come off at the end of 30 days or thereabouts most likely.

BTW, your gloating is adorable! Are you 13? I enjoy reading your hatred for this company and then your gloating when the price comes crashing down because it's like watching a child play a video game. The only reason the stock is down is because of the OTC helping out whiny shorts, and once the CE is lifted and the QB returns, all the brokers will again allow buying and the price will eventually return to the higher prices that made all the whiny shorts call in favors at the OTC in the first place.